GABPA Drug Discovery Landscape & Assay Solutions

By admin
20 Aug 2026
Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Transcription Factor Targeted Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for GABPA drug discovery. Select your modality below for heterodimer disruption, DNA-binding inhibition, or metabolic functional studies.

Component / Network	Product Description	Product Link
Antigen	GABPA Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native folding).	View GABPA Products
Partner Protein	GABPB1 Full-Length Protein Obligate heterodimer partner for PPI disruption assays. Theoretical MW confirmed.	View GABPB1 Products
Gene Delivery	GABPA Lentivirus Particles Full-length ORF for stable nuclear expression in metabolic assays.	View GABPA Products
Benchmark Ab	Anti-GABPA Benchmark Antibody Recombinant positive control for western blot and IP.	View GABPA Products
Validator	GABPA siRNA Set For knockdown verification and specificity checks.	View GABPA Products
Related Target A	TERT Downstream oncogenic target activated by GABPA in mutant promoters (e.g., Glioblastoma).	View TERT Products
Related Target B	GABPB1 Obligate heterodimer partner for GABPA DNA binding and activation.	View GABPB1 Products
Related Target C	GABPB2 Alternative heterodimer partner; potential compensatory resistance mechanism.	View GABPB2 Products
Related Target D	TFAM Mitochondrial transcription factor; downstream functional readout for GABPA inhibition.	View TFAM Products

Critical Assay Challenges and The TarMart Advantage

Critical Assay Challenge	The TarMart Advantage (Technical Spec)
Intracellular / Nuclear Target Evaluation	High-purity (>95%) recombinant GABPA for SPR and EMSA (Electrophoretic Mobility Shift Assays).
Protein-Protein Interaction Screening (GABPA-GABPB1)	Purified Full-Length GABPA & GABPB1 proteins (>95% purity) suitable for AlphaScreen/TR-FRET.
DNA-Binding Domain Inhibition	ETS domain fragment available with verified sequence for crystallization/SPR.
Nuclear Permeability Validation	Lentivirus for stable cell line construction; compatible with confocal localization assays.
Metabolic Functional Readout	High-expression lentivirus titer for OCR/ECAR analysis (Seahorse compatible).
Lack of Validated Controls	Sequence-verified Benchmark Antibodies included for reliable assay calibration.
False Positives in Knockdown Studies	Validated siRNA included for rigorous biological specificity checks.

Live GABPA R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race to drug transcription factors is intensifying. For GABPA (GA binding protein transcription factor alpha subunit), the focus is heavily rooted in precision oncology, particularly for tumors harboring TERT promoter mutations such as glioblastoma (GBM). Traditional approaches considered GABPA "undruggable," but the next wave of R&D is targeting the GABPA-GABPB1 protein-protein interaction and exploring Targeted Protein Degradation (PROTACs) to selectively ablate GABPA's ability to drive oncogenic TERT expression. As a master regulator of mitochondrial biogenesis via the GABPA/GABPB1 heterodimer, this target has also shifted from traditional oncology approaches toward metabolic reprogramming strategies in prostate cancer, glioblastoma, and breast cancer. The current landscape is dominated by early-stage small molecule inhibitors targeting the protein-protein interaction (PPI) interface and DNA-binding disruption, with major players exploring molecular glue and PROTAC modalities to overcome nuclear accessibility challenges. As first-generation PPI inhibitors enter preclinical validation, the next wave of R&D is targeting allosteric sites and combination therapies with mitochondrial complex inhibitors.

Competitive Modality & Indication Snapshot

Modality	Representative Players	Key Indications	Critical Assay Need (Why TarMart?)
Small Molecule (PPI Inhibitors)	Academic Spin-offs, Specialized Biotechs	Glioblastoma (TERT mutant tumors), Prostate Cancer	Interaction Screening (Need pure GABPA & GABPB1 proteins)
PROTAC / Molecular Glues	Targeted Degradation Biotechs	Solid Tumors, Refractory Tumors	Ubiquitination/Degradation Assays (Need pure recombinant proteins)
Nucleic Acid (siRNA/ASO)	RNAi Developers	Refractory Cancers	Knockdown Validation (Need Sequence Verified Antibodies & siRNA)
DNA-Binding Inhibitors	Early Discovery	Metabolic Cancers	EMSA/SPR (Need ETS domain protein)
Metabolic Combinations	Pharma Consortiums	OxPhos-Driven Cancers	Functional Validation (Need siRNA + ORF controls)

Key Functional Domains and Genetic Variants

GABPA (UniProt Q06546) contains a PNT (Pointed) domain critical for protein-protein interactions. Key genetic variants include dbSNP:rs2829897 and dbSNP:rs2829900, which may influence target function or drug response.